(IVZ) Invesco - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: BMG491BT1088
Mutual Funds, ETFs, Private Funds, Managed Portfolios
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.34% |
| Yield on Cost 5y | 4.89% |
| Yield CAGR 5y | 5.86% |
| Payout Consistency | 93.6% |
| Payout Ratio | 43.3% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 38.4% |
| Value at Risk 5%th | 59.1% |
| Relative Tail Risk | -6.38% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.47 |
| Alpha | 54.91 |
| CAGR/Max DD | 0.64 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.484 |
| Beta | 1.514 |
| Beta Downside | 1.812 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.52% |
| Mean DD | 13.44% |
| Median DD | 14.28% |
Description: IVZ Invesco January 06, 2026
Invesco Ltd. (NYSE:IVZ) is a global investment manager that serves a broad client base-including retail, institutional, high-net-worth, public entities, and sovereign wealth funds-through a suite of equity, fixed-income, multi-asset, and alternative strategies. The firm operates both mutual funds and ETFs, and it also manages private funds, deploying capital across public equities, bonds, commodities, and currencies, typically investing $5-$15 million per company.
As of the end of 2023, Invesco reported approximately $1.5 trillion in assets under management (AUM) and generated $6.4 billion in revenue, reflecting a 31 % operating margin. The asset-management sector is currently driven by fee compression from the shift toward low-cost passive products and heightened demand for ESG-aligned investments, which together influence net inflows and profit margins for firms like Invesco.
For a deeper quantitative assessment of Invesco’s valuation metrics, the ValueRay platform offers a concise dashboard you may find useful.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 1.05b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.52 > 1.0 |
| NWC/Revenue: 18.80% < 20% (prev 20.51%; Δ -1.71% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.39b > Net Income 1.05b |
| Net Debt (100.8m) to EBITDA (1.52b): 0.07 < 3 |
| Current Ratio: 1.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (454.6m) vs 12m ago -0.22% < -2% |
| Gross Margin: 35.41% > 18% (prev 0.32%; Δ 3509 % > 0.5%) |
| Asset Turnover: 22.45% > 50% (prev 21.41%; Δ 1.04% > 0%) |
| Interest Coverage Ratio: 18.85 > 6 (EBITDA TTM 1.52b / Interest Expense TTM 71.9m) |
Altman Z'' (< 1.1 .. > 2.6) 1.92
| A: 0.04 (Total Current Assets 2.68b - Total Current Liabilities 1.50b) / Total Assets 28.44b |
| B: 0.25 (Retained Earnings 7.17b / Total Assets 28.44b) |
| C: 0.05 (EBIT TTM 1.36b / Avg Total Assets 27.97b) |
| D: 0.48 (Book Value of Equity 6.55b / Total Liabilities 13.65b) |
| Altman-Z'' Score: 1.92 = BBB |
ValueRay F-Score (Strict, 0-100) 63.94
| 1. Piotroski: 7.50pt |
| 2. FCF Yield: 9.98% |
| 3. FCF Margin: 21.88% |
| 4. Debt/Equity: 0.12 |
| 5. Debt/Ebitda: 0.07 |
| 6. ROIC - WACC: -2.94% |
| 7. RoE: 7.34% |
| 8. Revenue Trend: -6.00% |
| 9. EPS Trend: -10.02% |
What is the price of IVZ shares?
As of January 23, 2026, the stock is trading at USD 29.17 with a total of 4,234,039 shares traded.
Over the past week, the price has changed by +3.26%, over one month by +6.69%, over three months by +28.28% and over the past year by +74.06%.
Over the past week, the price has changed by +3.26%, over one month by +6.69%, over three months by +28.28% and over the past year by +74.06%.
Is IVZ a buy, sell or hold?
Invesco has received a consensus analysts rating of 3.07.
Therefor, it is recommend to hold IVZ.
- Strong Buy: 1
- Buy: 1
- Hold: 11
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the IVZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29.1 | -0.2% |
| Analysts Target Price | 29.1 | -0.2% |
| ValueRay Target Price | 32.9 | 12.9% |
IVZ Fundamental Data Overview January 17, 2026
P/E Trailing = 19.9932
P/E Forward = 12.1507
P/S = 2.0877
P/B = 1.1897
P/EG = 0.5039
Revenue TTM = 6.28b USD
EBIT TTM = 1.36b USD
EBITDA TTM = 1.52b USD
Long Term Debt = 1.62b USD (from longTermDebt, last quarter)
Short Term Debt = 66.2m USD (from shortTermDebt, last fiscal year)
Debt = 1.62b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 100.8m USD (from netDebt column, last quarter)
Enterprise Value = 13.76b USD (13.11b + Debt 1.62b - CCE 973.1m)
Interest Coverage Ratio = 18.85 (Ebit TTM 1.36b / Interest Expense TTM 71.9m)
EV/FCF = 10.02x (Enterprise Value 13.76b / FCF TTM 1.37b)
FCF Yield = 9.98% (FCF TTM 1.37b / Enterprise Value 13.76b)
FCF Margin = 21.88% (FCF TTM 1.37b / Revenue TTM 6.28b)
Net Margin = 16.69% (Net Income TTM 1.05b / Revenue TTM 6.28b)
Gross Margin = 35.41% ((Revenue TTM 6.28b - Cost of Revenue TTM 4.05b) / Revenue TTM)
Gross Margin QoQ = 34.17% (prev 33.28%)
Tobins Q-Ratio = 0.48 (Enterprise Value 13.76b / Total Assets 28.44b)
Interest Expense / Debt = 1.58% (Interest Expense 25.7m / Debt 1.62b)
Taxrate = 25.16% (252.9m / 1.01b)
NOPAT = 1.01b (EBIT 1.36b * (1 - 25.16%))
Current Ratio = 1.79 (Total Current Assets 2.68b / Total Current Liabilities 1.50b)
Debt / Equity = 0.12 (Debt 1.62b / totalStockholderEquity, last quarter 14.01b)
Debt / EBITDA = 0.07 (Net Debt 100.8m / EBITDA 1.52b)
Debt / FCF = 0.07 (Net Debt 100.8m / FCF TTM 1.37b)
Total Stockholder Equity = 14.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.75% (Net Income 1.05b / Total Assets 28.44b)
RoE = 7.34% (Net Income TTM 1.05b / Total Stockholder Equity 14.28b)
RoCE = 8.52% (EBIT 1.36b / Capital Employed (Equity 14.28b + L.T.Debt 1.62b))
RoIC = 7.42% (NOPAT 1.01b / Invested Capital 13.67b)
WACC = 10.36% (E(13.11b)/V(14.73b) * Re(11.50%) + D(1.62b)/V(14.73b) * Rd(1.58%) * (1-Tc(0.25)))
Discount Rate = 11.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.17%
[DCF Debug] Terminal Value 73.98% ; FCFF base≈1.41b ; Y1≈1.74b ; Y5≈2.97b
Fair Price DCF = 75.68 (EV 33.79b - Net Debt 100.8m = Equity 33.68b / Shares 445.1m; r=10.36% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -10.02 | EPS CAGR: -8.75% | SUE: 3.09 | # QB: 1
Revenue Correlation: -6.00 | Revenue CAGR: -1.91% | SUE: 0.88 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.58 | Chg30d=+0.021 | Revisions Net=+3 | Analysts=6
EPS next Year (2026-12-31): EPS=2.62 | Chg30d=+0.116 | Revisions Net=+4 | Growth EPS=+32.0% | Growth Revenue=+14.6%
P/E Forward = 12.1507
P/S = 2.0877
P/B = 1.1897
P/EG = 0.5039
Revenue TTM = 6.28b USD
EBIT TTM = 1.36b USD
EBITDA TTM = 1.52b USD
Long Term Debt = 1.62b USD (from longTermDebt, last quarter)
Short Term Debt = 66.2m USD (from shortTermDebt, last fiscal year)
Debt = 1.62b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 100.8m USD (from netDebt column, last quarter)
Enterprise Value = 13.76b USD (13.11b + Debt 1.62b - CCE 973.1m)
Interest Coverage Ratio = 18.85 (Ebit TTM 1.36b / Interest Expense TTM 71.9m)
EV/FCF = 10.02x (Enterprise Value 13.76b / FCF TTM 1.37b)
FCF Yield = 9.98% (FCF TTM 1.37b / Enterprise Value 13.76b)
FCF Margin = 21.88% (FCF TTM 1.37b / Revenue TTM 6.28b)
Net Margin = 16.69% (Net Income TTM 1.05b / Revenue TTM 6.28b)
Gross Margin = 35.41% ((Revenue TTM 6.28b - Cost of Revenue TTM 4.05b) / Revenue TTM)
Gross Margin QoQ = 34.17% (prev 33.28%)
Tobins Q-Ratio = 0.48 (Enterprise Value 13.76b / Total Assets 28.44b)
Interest Expense / Debt = 1.58% (Interest Expense 25.7m / Debt 1.62b)
Taxrate = 25.16% (252.9m / 1.01b)
NOPAT = 1.01b (EBIT 1.36b * (1 - 25.16%))
Current Ratio = 1.79 (Total Current Assets 2.68b / Total Current Liabilities 1.50b)
Debt / Equity = 0.12 (Debt 1.62b / totalStockholderEquity, last quarter 14.01b)
Debt / EBITDA = 0.07 (Net Debt 100.8m / EBITDA 1.52b)
Debt / FCF = 0.07 (Net Debt 100.8m / FCF TTM 1.37b)
Total Stockholder Equity = 14.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.75% (Net Income 1.05b / Total Assets 28.44b)
RoE = 7.34% (Net Income TTM 1.05b / Total Stockholder Equity 14.28b)
RoCE = 8.52% (EBIT 1.36b / Capital Employed (Equity 14.28b + L.T.Debt 1.62b))
RoIC = 7.42% (NOPAT 1.01b / Invested Capital 13.67b)
WACC = 10.36% (E(13.11b)/V(14.73b) * Re(11.50%) + D(1.62b)/V(14.73b) * Rd(1.58%) * (1-Tc(0.25)))
Discount Rate = 11.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.17%
[DCF Debug] Terminal Value 73.98% ; FCFF base≈1.41b ; Y1≈1.74b ; Y5≈2.97b
Fair Price DCF = 75.68 (EV 33.79b - Net Debt 100.8m = Equity 33.68b / Shares 445.1m; r=10.36% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -10.02 | EPS CAGR: -8.75% | SUE: 3.09 | # QB: 1
Revenue Correlation: -6.00 | Revenue CAGR: -1.91% | SUE: 0.88 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.58 | Chg30d=+0.021 | Revisions Net=+3 | Analysts=6
EPS next Year (2026-12-31): EPS=2.62 | Chg30d=+0.116 | Revisions Net=+4 | Growth EPS=+32.0% | Growth Revenue=+14.6%
Additional Sources for IVZ Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle